The effect of fluorine-18 fluorodeoxyglucose positron emission tomography on the management of cutaneous malignant melanoma

Clinical Nuclear Medicine

Volumn 25, Issue 1, 2000, Pages 48-51

  Jadvar, Hossein ^a,c   Johnson, Denise L ^b   Segall, George M ^a  

^a VA PALO ALTO HEALTH CARE SYSTEM   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

FDG; Management; Melanoma; Positron Emission Tomography

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADULT; AGED; ARTICLE; ASPIRATION BIOPSY; CANCER IMMUNOTHERAPY; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; INTERMETHOD COMPARISON; JEJUNUM CANCER; LUNG METASTASIS; LYMPH NODE METASTASIS; MALE; MELANOMA; POSITRON EMISSION TOMOGRAPHY; RECURRENT CANCER; RETROSPECTIVE STUDY;

ADULT; AGED; AGED, 80 AND OVER; DEOXYGLUCOSE; FEMALE; FLUORINE RADIOISOTOPES; HUMANS; MALE; MELANOMA; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; RETROSPECTIVE STUDIES; SKIN NEOPLASMS; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0033963635     PISSN: 03639762     EISSN: None     Source Type: Journal    
DOI: 10.1097/00003072-200001000-00011     Document Type: Article

References (12)

1. Hoh CK, Hawkins RA, Glaspy JA, et al: Cancer detection with whole-body PET using 2-[18F]fluoro-2-deoxy-D-glucose. J Comput Assist Tomogr 17(4):582, 1993.
2. Blessing C, Feine U, Geiger L, et al: Positron emission tomography and ultrasonography. A comparative retrospective study assessing the diagnostic validity in lymph node metastases of malignant melanoma. Arch Dermatol 131:1394, 1995.
3. Steinert HC, Huch Boni RA, Buck A, et al: Malignant melanoma: Staging with whole-body positron emission tomography and 2-F-18]-fluoro-2-deoxy-D-glucose. Radiology 195:705, 1995.
4. Boni R, Boni RA, Steinert H, et al: Staging of metastatic melanoma by whole-body positron emission tomography using 2-fluorine-18-fluoro-2-deoxy-D-glucose. Br J Dermatol 132:556.
5. Gritters LS, Francis IR, Zasadny KR, Wahl RL: Initial assessment of positron emission tomography using 2-fluorine-18-fluoro-2-deoxy-D-glucose in imaging of malignant melanoma. J Nucl Med 34:1420, 1993.
6. Wagner JD, Schauwecker D, Hutchins G, Coleman JJ III: Initial assessment of positron emission tomography for detection of nonpalpable regional lymphatic metastases in melanoma. J Surg Oncol 64:181, 1997.
7. Argenyi EE, Dogan AS, Urdaneta LF, et al: Detection of unsuspected metastases in a melanoma patient with positron emission tomography. Clin Nucl Med 20:744, 1995.
8. Yao WJ, Hoh CK, Glaspy JA, et al: Whole-body FDG PET imaging for staging of malignant melanoma: Is it cost-effective? [Abstract]. J Nucl Med 35:8, 1994.
9. Daiman DL, Fulham MJ, Thompson E, Thompson JF: Positron emission tomography in the detection and management of metastatic melanoma. Melanoma Res 6:325, 1996.
10. Baum RP, Rinne D, Zollner TM, et al: F-18 FDG PET for staging of high risk melanoma and restaging of recurrences: Results of a prospective study and influence on therapeutic management [Abstract]. J Nucl Med 37:137P, 1996.
11. Valk PE, Segall GM, Johnson DL, et al: Cost-effectiveness of whole-body FDG PET imaging in metastatic melanoma [Abstract]. J Nucl Med 38:90P, 1997.
12. Valk PE, Pounds TR, Tesar RD, Hopkins DM, Haseman MK: Cost-effectiveness of PET imaging in clinical oncology. Nucl Med Biol 23:737, 1996. ECAT EXACT scanner (CTI, Knoxville, TN)